今日盘中，锦欣生殖（01951）股价大幅上涨，涨幅高达6.75%，引发市场关注。
这波涨势主要受到美银证券最新研报的推动。该券商发布报告称，将锦欣生殖的目标价从3港元上调至3.5港元，并维持"买入"评级。这一积极的分析师观点无疑增强了投资者对该股的信心。
根据美银证券的研究，尽管锦欣生殖去年的财务表现略显疲软，但其未来前景仍然看好。报告指出，公司2024年预订收入同比小幅增长0.8%至28.12亿元人民币，总利润同比下降6.5%至10.99亿元人民币，毛利率达39.1%。尽管如此，美银证券仍然看好公司的长期发展，这也解释了为什么在下调未来三年收入预测的同时，仍然选择上调目标价。这份报告为锦欣生殖股价的强劲表现提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.